Yasunaga Hideo, Ide Hiroo, Imamura Tomoaki
Department of Planning, Information, and Management, University of Tokyo Hospital, Tokyo.
J Cardiol. 2007 Feb;49(2):77-81.
Prices of medical devices in Japan were previously reported to be 2 to 4 times higher than those in the United States in 1996 and 1997. However, such data are out of date. We previously compared the market prices in early 2005 between Japan and the US for 16 items in 10 categories of medical materials, and showed that price differences still existed for all these items. However, the number of items investigated was small for each category, and generalization of the results might have been limited. The present study conducted a further investigation into price information for multiple items for each category, focusing on 5 cardiovascular devices.
The US market price information was obtained from interviews of a healthcare provider network and 2 different group-purchasing organizations. We could obtain price information on 19 items in 5 categories. We substituted the Japanese reimbursement prices for the Japanese market prices.
The price ratio (Japanese reimbursement price / US market price)was 2.0-3.5 for coronary stents, 5.9-6.8 for percutaneous transluminal coronary angioplasty catheters, 2.2-3.5 for pacemakers, 1.6-2.5 for mechanical valves, and 3.4-4.7 for oxygenators.
The price disparities for cardiovascular devices between Japan and the US were reconfirmed. Japan's healthcare system should establish group-purchasing organizations, promote centers of clinical excellence, and abolish regulation of parallel imports and protectionism under the Japanese Pharmaceutical Affairs Law.
此前有报道称,1996年和1997年日本医疗设备的价格比美国高出2至4倍。然而,此类数据已过时。我们之前比较了2005年初日本和美国10类医疗材料中16种产品的市场价格,结果表明所有这些产品仍存在价格差异。然而,每类产品的调查项目数量较少,结果的普遍性可能受到限制。本研究针对每类产品的多个项目进一步调查价格信息,重点关注5种心血管设备。
美国市场价格信息来自对一个医疗服务提供商网络和2个不同的集团采购组织的访谈。我们获得了5类19种产品的价格信息。我们用日本的报销价格替代日本市场价格。
冠状动脉支架的价格比(日本报销价格/美国市场价格)为2.0 - 3.5,经皮冠状动脉腔内血管成形术导管为5.9 - 6.8,心脏起搏器为2.2 - 3.5,机械瓣膜为1.6 - 2.5,氧合器为3.4 - 4.7。
再次证实了日本和美国心血管设备的价格差异。日本的医疗保健系统应建立集团采购组织,促进卓越临床中心的发展,并废除《日本药事法》对平行进口的监管和保护主义。